Ranbaxy Laboratories, Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories (RLL), announced the sales and promotion launch of Absorica (Isotretinoin) Capsules, a product that is licensed from Cipher Pharmaceuticals, Ontario. A Prabhudas Lilladher report anticipates that the product could become the largest selling product for the company in the US latest by 2014.
Absorica is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older. Due to its high lipophilicity, oral absorption of isotretinoin is enhanced when given with a high-fat meal, however, Absorica, which is formulated using patented lidose technology, can be given without regards to meals. The fasted AUC0-t of Absorica is approximately 83 per cent greater than that of Accutane, while both products are bioequivalent under fed conditions. Absorica is therefore not interchangeable and not substitutable with generic products of Accutane. Absorica, NDA, was approved based on a large pivotal clinical trial enrolling 925 patients.
Dr Ashish Anvekar, Senior Director, Ranbaxy Laboratories Inc said, “We are most pleased to make Absorica available as a valuable option for dermatologists and a subset of patients who suffer from severe recalcitrant nodular acne. Absorica will be the flagship brand of the Ranbaxy dermatology product portfolio in the US.”
EP News Bureau – Mumbai
